Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 4/20 | 0.57 |
| ▸ | CDK9 | P50750 | 4/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | PTPRC | P08575 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063235 | 0.79 | GSK3B (0.61) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL7815802 | 0.75 | CCNT1 (0.66) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL6099227 | 0.74 | CCNE2 (0.80) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL7195024 | 0.72 | CCNT1 (0.76) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL6097272 | 0.72 | CDK4 (0.55) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL28503706 | 0.72 | CCNE2 (0.62) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL8161370 | 0.71 | CCNT1 (0.56) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL5686048 | 0.71 | CCNE2 (1.00) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL30319849 | 0.71 | CCNE2 (1.00) | CDK2CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL28505491 | 0.71 | CDK2 (0.60) | CCNT1CDK9CDK2CCNE2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057052-B2 | Heterocyclic quinones as pharmaceutical agents | DUKE UNIVERSITY (US) | 2006-06-06 | — | — | US | disclosed |
| WO-2004050014-A2 | SETEROCYCLIC QUINONES AS PHARMACEUTICAL AGENTS | DUKE UNIVERSITY (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040063774-A1 | Heterocyclic quinones as pharmaceutical agents | DUKE UNIVERSITY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063774-A1 | Heterocyclic quinones as pharmaceutical agents | NQO1, RECQL, SDHA | CCNT1 173/4885CDK9 132/4885CDK2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.